|
News: AMT Suspends Glybera and Plans 50% Job Cuts in Restructuring Moves
|
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today provided an update on operations and disclosed the outcome of a strategic review of its gene therapy product pipeline conducted by management and AMT's Board of Directors that enables the company to remain at the forefront of gene therapy development. The CHMP's recent opinion, while not approving Glybera®, did not identify any safety risks with AMT's adeno-associated virus vector technology. This will allow AMT to leverage its expertise and strength in building other portfolio products. The selection of specific pipeline products is aimed at securing partnering agreements that will provide solid financial foundations to take the company forward. Existing shareholders continue to see promise in the technology and are in discussions with AMT to provide additional equity.
Read more... |
|
News: Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
|
Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has maintained its earlier opinion that Glybera (alipogene tiparvovec) is not approvable at this time. The decision was made contrary to the positive recommendation of CHMP Rapporteurs, the Scientific Advisory Group (SAG), an expert panel specifically selected to evaluate clinical results and the science of the product, and the Committee for Advanced Therapies (CAT), which provides guidance on advanced therapeutics such as gene and cell therapy.
Read more... |
|
Conferences
|
| - |
16 - 18 November 2011, 10th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases. Focus Topic: Cell Trafficking and the Niche, Sonoma, CA |
| - |
18 November 2011, 10th symposium of the Association de Thérapie Génique du Québec (ATGQ), Québec, Canada |
| - |
15 - 16 December 2011, NIH Symposium: RNA Oligonucleotides - Emerging Clinical Applications, Rockville, MD |
| - |
30 January - 1 February 2012, Phacilitate 8th Annual Cell & Gene Therapy Forum 2012, Washington DC, MD |
| - |
2 -5 February 2012, Up Close and Personalized, International Congress on Personalized Medicine, Florence, Italy |
| - |
15 - 17 March 2012, 18th Annual Meeting of the German Society for Gene Therapy (DG-GT), Frankfurt/Main, Germany |
| - |
16 – 19 May 2012, American Society of Gene and Cell Therapy (ASGCT) 15th Annual Meeting, Philadelphia, PA |
| - |
5 – 8 June 2012, International Society for Cellular Therapy (ISCT) 18th Annual Meeting, Seattle, WA |
| - |
28 – 30 June 2012, The 18th Annual Meeting of the Japan Society of Gene Therapy (JSGT), Kumamoto University, Kumamoto, Japan |
| - |
5 – 6 October 2012, International Society for Cell & Gene Therapy of Cancer - 2012 Singapore Conference, Singapore |
| - |
26 – 29 October 2012, European Society Of Gene & Cell Therapy (ESGCT) XXth annual meeting and the French Society of Cell and Gene Therapy (SFTCG) collaborative Congress 2012, Versailles, France |
Read more... |
|
|
